Refine/Revise Search
Asking Price: $349,500

Current Custom Chemical Database - 15M products

Not Disclosed, CA
San diego County

E-Commerce Custom Chemical Database - 15M products with specsReady for re-boot. Extremely impressive ROBUST e-commerce platform integrated with products, vendors and customers. Company served life sciences specializing in catalog compounds, reference standards and custom synthesis for chemicals, biologics and medicinal compounds used for discovery research and development in pharmaceutical, biotech and defense industries.It was founded in 2005 and was operational between 2009 and 2018 in US. Back off in India stayed open until August 2020. In its best year, the company generated over $1M in revenue. Typical years resulted in $550-$650k in revenue. Gross profit average was about 75%. The officers are now selling the assets of the business due to illness and family matters out of the country.It was the largest provider of pharmaceutical preparations. It offered orthogonally protected diamines, novel amines, chiral synthesis, enzymatic resolutions, amino acids, ketones, boronic acids, and unnatural alpha preparations for about 3000 paying clients. It started to make anti-cancer compounds.They procured materials from India, China, Europe and Korea by leveraging their online chemical price enquiry services to order from anywhere in the US and throughout the world from about 7000 vendors and created custom compounds in house.Most of the value is in the interactive AWS e-commerce data base with approximately 15,000,000 products developed over 3.5 years. It is current and updated real-time to the Amazon Scientific Site with accurate data requirements and detailed specifications for each chemical with associated quality control parameters, certificate of analysis and safety data sheet. It provides 'one-stop' shopping when an array of chemicals are required by the same customer. Products are searchable by a variety of methods including by use (ie. marijuana) or disease (i.e. alzheimers).There is a separate service with an extensive mailing list of about 2M targets. Receipient can click image that is hyperlinked to the product data base to search and place an order.In addition to the data base, approximately 6000 chemical compounds, worth $350,000 at cost, of salable inventory is available. These custom chemicals are stored in freezers with detail documented in quick books and back up on the database.The company name is recognized in the industry and could transfer along with office/lab space in San Diego that is extremely well suited for the business should a buyer wish to resume prior operations. Current rent on 1373 sqft is $1,925. Value of FFE is estimated at $25,000. A hazmat license, easily acquired for about $325, is required for shipping hazmat products by Federal Express but all other products may be shipped without a license. Very low cost overseas staff is also available to continue building the database along with on-going advisory support from the seller.Transitional support negotiable. Asking: $349,500.

Cash Flow Not Disclosed
Revenue Not Disclosed
$ Owner Financing Available

Asking Price: $22,500,000

Tech First Design-Build Construction Co. Strong

San Francisco, CA
San francisco County

The real estate market in California is a well-known and worldwide sensation. For any established Construction Company within the CA landscape, depending on the size of the Company, the gravity of that statement may or may not make sense to them. The Company we are representing has a very good understanding of that statement. Today’s residential construction space is highly segmented with a wide range of market participants, some with little experience within their field and some that can offer a wide range service options, and are endorsed by decades of high-profile experience. The Company we are representing is a Design-Build general Construction Company. The Design-Build process is renowned for bringing together and combining the skills of Architects, Designers, and Construction professionals all under roof to complete a single job in an efficient and diligent fashion. This Company, since their inception in 2014 has been offering custom installations in this Design-Build space. With the management team in possession of over 20 years in total Construction experience, and in utilizing a process that combines not two but three of the aspects needed for planning a standard build-out (Architecture, Design, and Construction) this Company has been able to more than double their revenues Y-O-Y since they first opened their doors nearly six years ago.What is more impressive, they have secured a total gross sales for the duration of next year (2020) of $7MM in future customer contracts (typical net-margin for the Company after expenses is 30%). Meaning, that a new Owner would be able to begin their move in a position without the concern or doubt of whether they would be able to post the same figures that the Company has been able to post in the past. Even more fascinating is that with the work load of these secured contracts, there is still room for taking on additional projects.Additionally, the management style of the Company a bottom-up and then top-down approach; employee's first. Meaning, each employee is to 'own' their position, and once fully trained, there is little need for oversite within every step in the chain in command. Every employee is trained with their thorough employee handbook, and is allowed in the field only when proven that they have a full understanding of the Company culture and understand best practices on a job site. A new owner would be in place mainly for overall leadership skills and overall Company direction.Today, mass production type of builders are vying for the high-end business opportunities available in the marketplace by attempting to advertise their services as a custom builder. While some may argue that the Construction marketplace is encountering little growth, it is Consumers seeking a more customized and the builders that can offer customized options that are seeing healthy growth and margins. Today's home builder is seeking an approach that incorporates technologies (within the service schedule and the overall build) and products that can bring their properties into the 21st (sustainable & efficient) and for many years after.The amount of stellar reviews that this Company has earned up to this point in time is absolutely inconceivable, until you see them for yourself. They're at a point in time that they can secure contracts for a whole year from today and people will wait for their services, literally for months before they can begin the process with them. At times they are even forced to turn business away. The Company in its current form can be taken in many different directions and by adding more of what is already structurally integrated with the Company, have the ability to grow rapidly. NDA is required for comprehensive CIM and any other due diligence documents on file with ProNova Partners.

Cash Flow $5,000,000
Revenue $13,000,000
$ Owner Financing Available

Asking Price: $349,500

Two JM Submarine Shops near City of Industry

Not Disclosed, CA
Los angeles County

Incredibly rare opportunity to own two JM submarine sandwich shops. Highly respected and popular brand. Stores are in and around City of Industry, LA County. 2017 gross $1,218,165, 2018 gross $1,246,462.. Each store is cash flow positive. 2018 SDE $77,549. Priced to sell now at $349,500 for both! SBA Possible.Stores have been absentee owned but not recommended. Transitioning buyer can step into this startup/turnaround operation without the financial and time investment required to launch from scratch. New So. CA franchises are currently requiring an investment of about $400k per store to launch new plus at least 6 months to identify location, negotiate leases, tenant improvement/build out, recruiting, hiring and training - just to get the doors open.Move in ready (approx.2&4 years new). Originally 20 year leases including the renewal options on 1100 and 1200 sqft respectively. Solid locations. New office complex is adding 1000 potential customers across from one of the stores this year. Hwy construction near the other will complete soon streamlining traffic flow into the center.LA territories are otherwise sold out! Opportunities for additonal stores once you are 'in the system' but no other way to enter the JM system in LA from 'the outside'.22-24 employees, 6 key holders. FFE estimated at $80k, Approximately $20k inventory. FFE available for purchase for 3rd store (currently in storage) - $25k.Stores are positioned for significant growth with appropriate owner operator focus on catering, delivery and foot traffic. As few as 25 additional sandwich sales per store per day will make a significant impact on profitability (all profit less COGS). As profitability improves, price will increase so serious buyers should not wait.Seller motivated as family has other business interests. Serious inquiries from those prepared to act immediately will be prioritized.

Cash Flow $77,549
Revenue $1,246,462

Asking Price: $199,000

Home Health Care Management

Not Disclosed, CA
San diego County

California Licensed Non-Medical In-Home Care-Life Care Management company.This company was founded in 2009. Company has specialized in the total care oversight of frail older adults. Service offerings have included: Life Care Management, Non-medical Home Care Aides and Referral and placement.Care Management includes; assessment and care planning, on-going care coordination by touching the physical, mental, social and spiritual needs of clients. The life care manager serves as liaison and advocate between the client, family and healthcare providers.Non-Medical Home Care Aides: Offers both companion and personal care services in the client home. Services range from light housekeeping, errands, meal preparation to hands on assistance. Which includes activities of daily living such as grooming and hygiene to full end of life care. The care aides can service can range from 2-3 hours to 24 hour live in care.Referral and Placement: Referral fee paid by contracted retirement living facilities. This is a Free service to assist clients and families in securing suitable retirement living which is customized to their individual needs. Currently 13 clients are receiving inhome care. In addition, the company has 13 active field employees others available as needed. Owner works full time in the business and wants to explore other opportunities.Appropriate for home based operation (assuming a 3rd party office for occasional meetings) or fold into existing operation. This is not appropriate for individuals not already experienced in the business.Projected 2019 Revenue $700k, potential earnings $150k (assumes home based with owner - operator). Company restructured early 2019 so historic data, though available is no longer relevant. Asking Price is $199,000.

Cash Flow $150,000
Revenue $700,000
$ Owner Financing Available

Asking Price: $20,000,000

Patented Universal Tumor-Targeting Drug Delivery

Irvine, CA
Orange County

Patented Universal Tumor-Targeting Drug Delivery Platform Co.This pharmaceutical company has developed and patented a universal tumor-targeting drug-delivery platform that can improve the safety and efficacy of many existing chemo treatments, with the ability to target numerous different types of cancer. The technology encapsulates existing FDA-approved drugs inside lipid nanoparticles (liposomes or emulsions) coated with patented human-sourced antinuclear antibodies (ANA). The lipid nanoparticle provides long-term storage stability of the drug and controlled release of the drug over time at body-temperature, and is expected to improve the safety and efficacy profile of the drug, including passive accumulation at the tumor while not harming normal tissues. The Company’s ANA, sourced from lupus patients, binds to nuclear material present in abundance in areas of necrosis (dead / ruptured cells) present in and around all solid tumors, thus anchoring the drug-filled nanoparticles at the tumor where the nanoparticle is designed to slowly release the drug directly on the tumor for more effect. As the Company’s ANA is not tumor-marker specific, but rather targets necrosis present in solid tumors, the technology is designed to 'universally' target many different types of cancer including breast cancer, lung, ovarian, colon, prostate, etc., as well as rare childhood cancers.The Company completed a successful proof-of-concept study at Children's Hospital using Ewing's Sarcoma transplanted in immunodeficient mice. Treatment with the Company's forumlation significantly inhibited tumor growth and extended survival times compared to control mice receiving no treatment or treatment with plain liposomal doxorubicin.The Company has been granted Orphan Drug Designation by the FDA on 2 of the lead drug formulations, providing FDA fee waivers, priority review, and 7-years exclusivity upon market approval. The orphan pathway also enables the potential for New Drug Approval after successful completion of Phase 2 studies, with Phase III data collected while in the market, thus significantly lowering the time and cost to market approval. This same drug inside the Company's tumor targeting delivery system will likely have potential to treat other pediatric cancers, and/or cancers in larger adult populations.As the Company’s platform and ANA has the potential to improve the safety and efficacy of many existing FDA approved drugs or even compounds in development, the Company anticipates the potential for multiple licensing agreements with multiple pharmaceutical companies seeking to improve their existing portfolio and extend patient life as they advance into clinical stage. And as it may be possible to file for New Drug Approval following successful Phase II studies, the Company anticipates licensing potential at early clinical stage. Multiple exit opportunities exist with high impact & high ROI.The Company is seeking a supportive capital partner to maintain momentum up to $20M. Funding will be used to advance the lead drug through formal Investigational New Drug enabling studies towards New Drug Approval; estimating $3-5 Million now to advance into clinical studies. Preclinical / animal studies estimate ($3 - 5 Million and 12-18 months); followed by potential combined Phase I-II clinical study in a rare cancer (approximately 2-3 years and $10M) to potential New Drug Approval, plus additional capital to advance additional drugs in the pipeline simultaneously, thus adding tremendous value to the Company’s valuation. Valuations of pharma companies often exceed $100 Million valuation at Phase I (approximately 18 months), and New Drug Approval can exceed valuations above $1 Billion. The Company has numerous, improved high-impact cancer drugs advancing with proper support.NDA is required for comprehensive Confidential Information Memorandum crafted by ProNova Partners.

Cash Flow Not Disclosed
Revenue Not Disclosed
$ Owner Financing Available

loading...
TOP ▲
Add Businesses and/or Franchises
To Basket For Free Information

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our cookies information for more details.